123 related articles for article (PubMed ID: 32965131)
1. The economic impact of disease progression and death in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients: using Korean nationwide health insurance claims data.
Park SK; Park JA; Yang SY; Shin JY; Koh H
Curr Med Res Opin; 2020 Nov; 36(11):1825-1833. PubMed ID: 32965131
[TBL] [Abstract][Full Text] [Related]
2. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.
Gauthier G; Gagnon-Sanschagrin P; Guérin A; Burne R; Small T; Niravath P; Dalal AA
Adv Ther; 2018 Apr; 35(4):503-514. PubMed ID: 29556908
[TBL] [Abstract][Full Text] [Related]
3. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
4. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
[TBL] [Abstract][Full Text] [Related]
5. HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study of Healthcare Costs in the Targeted-Therapy Age.
Sussell JA; Sheinson D; Wu N; Shah-Manek B; Seetasith A
Adv Ther; 2020 Apr; 37(4):1632-1645. PubMed ID: 32172510
[TBL] [Abstract][Full Text] [Related]
6. Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran.
Ansaripour A; Zendehdel K; Tadayon N; Sadeghi F; Uyl-de Groot CA; Redekop WK
PLoS One; 2018; 13(10):e0205079. PubMed ID: 30273393
[TBL] [Abstract][Full Text] [Related]
7. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Xie J; Diener M; De G; Yang H; Wu EQ; Namjoshi M
J Med Econ; 2013; 16(2):278-88. PubMed ID: 23153318
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study.
Chen HM; Chen JH; Chiang SC; Lin YC; Ko Y
Medicine (Baltimore); 2021 Oct; 100(43):e27567. PubMed ID: 34713830
[TBL] [Abstract][Full Text] [Related]
9. Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2(-) metastatic breast cancer.
Engel-Nitz NM; Hao Y; Becker LK; Gerdes R
J Comp Eff Res; 2015 Aug; 4(4):303-14. PubMed ID: 26274792
[TBL] [Abstract][Full Text] [Related]
10. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry.
Baser O; Wei W; Henk HJ; Teitelbaum A; Xie L
Curr Med Res Opin; 2012 Mar; 28(3):419-28. PubMed ID: 22364568
[TBL] [Abstract][Full Text] [Related]
11. The economic burden of metastatic breast cancer in Spain.
Bermejo de Las Heras B; Cortes Ramon Y Cajal J; Galve Calvo E; de la Haba Rodriguez J; Garcia Mata J; Moreno Anton F; Pelaez Fernandez I; Rodriguez-Lescure A; Rodriguez Sanchez CA; Ruiz-Borrego M; Remak E; Barra M; Rivero M; Soto Alvarez J
Eur J Hosp Pharm; 2020 Jan; 27(1):19-24. PubMed ID: 32064084
[TBL] [Abstract][Full Text] [Related]
12. Healthcare cost of HER2-positive and negative breast tumors in the United States (2012-2035).
Tartari F; Santoni M; Pistelli M; Berardi R
Cancer Treat Rev; 2017 Nov; 60():12-17. PubMed ID: 28863312
[TBL] [Abstract][Full Text] [Related]
13. Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; de Groot S; Riemsma R; Fayter D; Armstrong N; Portegijs P; Duffy S; Kleijnen J; Al MJ
Pharmacoeconomics; 2019 Feb; 37(2):141-153. PubMed ID: 30194622
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study.
Baffert S; Cottu P; Kirova YM; Mercier F; Simondi C; Bachelot T; Le Rhun E; Levy C; Gutierrez M; Madranges N; Moldovan C; Coudert B; Spaëth D; Serin D; Cotté FE; Benjamin L; Maillard C; Laulhere-Vigneau S; Durand-Zaleski I
BMC Health Serv Res; 2013 Oct; 13():456. PubMed ID: 24176086
[TBL] [Abstract][Full Text] [Related]
16. Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective.
Xie J; Hao Y; Zhou ZY; Qi CZ; De G; Glück S
Clin Breast Cancer; 2015 Oct; 15(5):e263-76. PubMed ID: 26048087
[TBL] [Abstract][Full Text] [Related]
17. HR+/HER2- Metastatic Breast Cancer: Epidemiology, Prescription Patterns, Healthcare Resource Utilisation and Costs from a Large Italian Real-World Database.
Piccinni C; Dondi L; Ronconi G; Calabria S; Pedrini A; Esposito I; Martini N; Marangolo M
Clin Drug Investig; 2019 Oct; 39(10):945-951. PubMed ID: 31347036
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
[TBL] [Abstract][Full Text] [Related]
20. ReCAP: Treatment Patterns and Cost of Care Associated With Initial Therapy Among Patients Diagnosed With Operable Early-Stage Human Epidermal Growth Factor Receptor 2-Overexpressed Breast Cancer in the United States: A Real-World Retrospective Study.
DaCosta Byfield S; Buck PO; Blauer-Peterson C; Poston SA; DaCosta Byfield S; Buck PO; Blauer-Peterson C; Poston SA
J Oncol Pract; 2016 Feb; 12(2):159-67. PubMed ID: 26395563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]